Tara L Spires-Jones

List of Publications by Year
in descending order

161 papers	18,040 citations	15504 65 h-index	14208 128 g-index
195 all docs	195 docs citations	195 times ranked	17902 citing authors

#	Article	IF	Citations
1	Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function. Science, 2005, 309, 476-481.	12.6	1,766
2	Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. Neuron, 2012, 73, 685-697.	8.1	1,191
3	Rapid appearance and local toxicity of amyloid-Î² plaques in a mouse model of Alzheimerâ€™s disease. Nature, 2008, 451, 720-724.	27.8	916
4	The Intersection of Amyloid Beta and Tau at Synapses in Alzheimerâ€™s Disease. Neuron, 2014, 82, 756-771.	8.1	862
5	Oligomeric amyloid Î² associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4012-4017.	7.1	734
6	Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy. Journal of Neuroscience, 2005, 25, 7278-7287.	3.6	524
7	Caspase activation precedes and leads to tangles. Nature, 2010, 464, 1201-1204.	27.8	463
8	Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nature Cell Biology, 2007, 9, 139-148.	10.3	399
9	The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System. American Journal of Pathology, 2012, 181, 1426-1435.	3.8	369
10	Region-specific Dissociation of Neuronal Loss and Neurofibrillary Pathology in a Mouse Model of Tauopathy. American Journal of Pathology, 2006, 168, 1598-1607.	3.8	349
11	Environmental Enrichment Rescues Protein Deficits in a Mouse Model of Huntington's Disease, Indicating a Possible Disease Mechanism. Journal of Neuroscience, 2004, 24, 2270-2276.	3.6	342
12	Amyloid Î² Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation. Journal of Neuroscience, 2010, 30, 2636-2649.	3.6	328
13	Tau association with synaptic vesicles causes presynaptic dysfunction. Nature Communications, 2017, 8, 15295.	12.8	289
14	Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathologica, 2017, 134, 187-205.	7.7	288
15	Tau pathophysiology in neurodegeneration: a tangled issue. Trends in Neurosciences, 2009, 32, 150-159.	8.6	284
16	Apolipoprotein E4 effects in Alzheimerâ€™s disease are mediated by synaptotoxic oligomeric amyloid-Î². Brain, 2012, 135, 2155-2168.	7.6	268
17	Alzheimer's disease: synapses gone cold. Molecular Neurodegeneration, 2011, 6, 63.	10.8	250
18	Beyond the neuronâ€“cellular interactions early in Alzheimer disease pathogenesis. Nature Reviews Neuroscience, 2019, 20, 94-108.	10.2	237

#	Article	IF	Citations
19	Nanoparticles enhance brain delivery of bloodâ€“brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18837-18842.	7.1	228
20	Tau Accumulation Causes Mitochondrial Distribution Deficits in Neurons in a Mouse Model of Tauopathy and in Human Alzheimer's Disease Brain. American Journal of Pathology, 2011, 179, 2071-2082.	3.8	224
21	The physiological roles of tau and AÎ²: implications for Alzheimerâ€™s disease pathology and therapeutics. Acta Neuropathologica, 2020, 140, 417-447.	7.7	221
22	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid Î² Peptide. Journal of Neuroscience, 2012, 32, 15181-15192.	3.6	219
23	Soluble forms of tau are toxic in Alzheimerâ€™s disease. Translational Neuroscience, 2012, 3, 223-233.	1.4	185
24	The clinical promise of biomarkers of synapse damage or loss in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 21.	6.2	183
25	Transgenic models of Alzheimerâ€™s disease: Learning from animals. NeuroRx, 2005, 2, 423-437.	6.0	180
26	Impaired Spine Stability Underlies Plaque-Related Spine Loss in an Alzheimer's Disease Mouse Model. American Journal of Pathology, 2007, 171, 1304-1311.	3.8	179
27	Amyloid accelerates tau propagation and toxicity in a model of early Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2015, 3, 14.	5.2	176
28	Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. European Journal of Neuroscience, 2004, 19, 2799-2807.	2.6	172
29	TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. Neuron, 2017, 95, 297-308.e6.	8.1	171
30	Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 510-514.	7.1	170
31	Pathological Tau Disrupts Ongoing Network Activity. Neuron, 2015, 85, 959-966.	8.1	152
32	Alzheimer's Therapeutics Targeting Amyloid Beta 1â€“42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. PLoS ONE, 2014, 9, e111899.	2.5	151
33	Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau. Neuron, 2018, 97, 823-835.e8.	8.1	151
34	Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. Science Translational Medicine, 2013, 5, 212ra161.	12.4	135
35	In VivoImaging Reveals Dissociation between Caspase Activation and Acute Neuronal Death in Tangle-Bearing Neurons. Journal of Neuroscience, 2008, 28, 862-867.	3.6	132
36	The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Research Reviews, 2013, 12, 757-763.	10.9	130

#	Article	IF	Citations
37	Differential effect of threeâ€repeat and fourâ€repeat tau on mitochondrial axonal transport. Journal of Neurochemistry, 2009, 111, 417-427.	3.9	123
38	Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimerâ€™s Disease. Cell Reports, 2019, 29, 3592-3604.e5.	6.4	123
39	Synaptic pathology: A shared mechanism in neurological disease. Ageing Research Reviews, 2016, 28, 72-84.	10.9	122
40	Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology, 2013, 38, 2462-2475.	2.7	118
41	Spines, Plasticity, and Cognition in Alzheimer's Model Mice. Neural Plasticity, 2012, 2012, 1-10.	2.2	117
42	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Molecular and Cellular Proteomics, 2019, 18, 546-560.	3.8	115
43	Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO Journal, 2015, 34, 3028-3041.	7.8	112
44	PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathologica, 2020, 139, 503-526.	7.7	110
45	Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. Nature Neuroscience, 2012, 15, 1422-1429.	14.8	108
46	Human Brain-Derived AÎ² Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. Journal of Neuroscience, 2017, 37, 11947-11966.	3.6	108
47	Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. BMC Neuroscience, 2008, 9, 34.	1.9	104
48	Synaptic alterations in the rTg4510 mouse model of tauopathy. Journal of Comparative Neurology, 2013, 521, 1334-1353.	1.6	98
49	Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathologica, 2018, 135, 213-226.	7.7	97
50	Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and AÃŸ pathology. Nature Communications, 2022, 13, 135.	12.8	97
51	Neuronal Structure is Altered by Amyloid Plaques. Reviews in the Neurosciences, 2004, 15, 267-278.	2.9	96
52	Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2019, 45, 327-346.	3.2	96
53	Studying synapses in human brain with array tomography and electron microscopy. Nature Protocols, 2013, 8, 1366-1380.	12.0	95
54	Are Tangles as Toxic as They Look?. Journal of Molecular Neuroscience, 2011, 45, 438-444.	2.3	93

#	Article	IF	Citations
55	Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 3176-3192.	3.6	92
56	Rapid Î²-Amyloid Deposition and Cognitive Impairment After Cholinergic Denervation in APP/PS1 Mice. Journal of Neuropathology and Experimental Neurology, 2013, 72, 272-285.	1.7	91
57	Synaptic phosphorylated Î±-synuclein in dementia with Lewy bodies. Brain, 2017, 140, 3204-3214.	7.6	90
58	Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimerâ€™s disease model. Acta Neuropathologica, 2014, 127, 257-270.	7.7	88
59	Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Journal, 2005, 272, 2347-2361.	4.7	87
60	Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 747-757.	7.7	87
61	Propagation of tau pathology in Alzheimerâ€™s disease: identification of novel therapeutic targets. Alzheimer's Research and Therapy, 2013, 5, 49.	6.2	84
62	Human tau increases amyloid Î² plaque size but not amyloid Î²â€mediated synapse loss in a novel mouse model of Alzheimer's disease. European Journal of Neuroscience, 2016, 44, 3056-3066.	2.6	81
63	Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. Neurobiology of Disease, 2011, 41, 650-654.	4.4	80
64	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 146.	5.2	79
65	An epigenetic predictor of death captures multi-modal measures of brain health. Molecular Psychiatry, 2021, 26, 3806-3816.	7.9	77
66	Soluble tau Species, Not Neurofibrillary Aggregates, Disrupt Neural System Integration in a tau Transgenic Model. Journal of Neuropathology and Experimental Neurology, 2011, 70, 588-595.	1.7	74
67	TAR-DNA Binding Protein 43 in Pick Disease. Journal of Neuropathology and Experimental Neurology, 2008, 67, 62-67.	1.7	72
68	Tangle-Bearing Neurons Survive Despite Disruption of Membrane Integrity in a Mouse Model of Tauopathy. Journal of Neuropathology and Experimental Neurology, 2009, 68, 757-761.	1.7	69
69	Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiology of Disease, 2009, 33, 213-220.	4.4	66
70	Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid-Î² in Human Alzheimer Brain. PLoS ONE, 2011, 6, e14586.	2.5	66
71	Non-Fibrillar Oligomeric Amyloid-Î² within Synapses. Journal of Alzheimer's Disease, 2016, 53, 787-800.	2.6	65
72	Comparative profiling of the synaptic proteome from Alzheimerâ€™s disease patients with focus on the APOE genotype. Acta Neuropathologica Communications, 2019, 7, 214.	5.2	63

#	Article	IF	Citations
73	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in AlzheimerÂ¿s disease. Acta Neuropathologica Communications, 2014, 2, 146.	5.2	60
74	Brain interstitial oligomeric amyloid Î² increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB Journal, 2013, 27, 3239-3248.	0.5	57
75	A Reporter of Local Dendritic Translocation Shows Plaque- Related Loss of Neural System Function in APP-Transgenic Mice. Journal of Neuroscience, 2009, 29, 12636-12640.	3.6	54
76	Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early <scp>A</scp>lzheimer's disease. Synapse, 2017, 71, e21965.	1.2	53
77	Nanoscale structure of amyloid-Î² plaques in Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 5181.	3.3	52
78	Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2017, 54, 3428-3438.	4.0	50
79	Inhibition of Sirtuin 2 with Sulfobenzoic Acid Derivative AK1 is Non-Toxic and Potentially Neuroprotective in a Mouse Model of Frontotemporal Dementia. Frontiers in Pharmacology, 2012, 3, 42.	3.5	45
80	Neuropathology of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 233-243.	1.8	44
81	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimer's and Dementia, 2021, 17, 1365-1382.	0.8	43
82	Reversal of Neurofibrillary Tangles and Tau-Associated Phenotype in the rTgTauEC Model of Early Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 13300-13311.	3.6	42
83	Clusterin accumulates in synapses in Alzheimerâ€™s disease and is increased in apolipoprotein E4 carriers. Brain Communications, 2019, 1, fcz003.	3.3	42
84	Lowering Synaptogyrin-3 expression rescues Tau-induced memory defects and synaptic loss in the presence of microglial activation. Neuron, 2021, 109, 767-777.e5.	8.1	41
85	Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain. Neuroscience Letters, 2011, 487, 260-263.	2.1	40
86	Tau Causes Synapse Loss without Disrupting Calcium Homeostasis in the rTg4510 Model of Tauopathy. PLoS ONE, 2013, 8, e80834.	2.5	38
87	Characterisation of an inflammation-related epigenetic score and its association with cognitive ability. Clinical Epigenetics, 2020, 12, 113.	4.1	38
88	Selective vulnerability of inhibitory networks in multiple sclerosis. Acta Neuropathologica, 2021, 141, 415-429.	7.7	37
89	Reflections on the past two decades of neuroscience. Nature Reviews Neuroscience, 2020, 21, 524-534.	10.2	35
90	Synapse Density and Dendritic Complexity Are Reduced in the Prefrontal Cortex following Seven Days of Forced Abstinence from Cocaine Self-Administration. PLoS ONE, 2014, 9, e102524.	2.5	35

#	Article	IF	Citations
91	Environmental Enrichment Reduces Neuronal Intranuclear Inclusion Load But Has No Effect on Messenger RNA Expression in a Mouse Model of Huntington Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 817-827.	1.7	33
92	Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neuroscience Letters, 2014, 562, 63-68.	2.1	33
93	Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimerâ€™s Disease and Type 2 Diabetes. Molecular Neurobiology, 2018, 55, 6130-6144.	4.0	30
94	Trajectories of inflammatory biomarkers over the eighth decade and their associations with immune cell profiles and epigenetic ageing. Clinical Epigenetics, 2018, 10, 159.	4.1	30
95	Carboxy Terminus Heat Shock Protein 70 Interacting Protein Reduces Tau-Associated Degenerative Changes. Journal of Alzheimer's Disease, 2015, 44, 937-947.	2.6	29
96	Tauâ€“amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloidâ€induced disruption of axonal projections and exacerbated axonal pathology. Journal of Comparative Neurology, 2013, 521, 4236-4248.	1.6	28
97	Inhibitory synapse loss and accumulation of amyloid beta in inhibitory presynaptic terminals in Alzheimer's disease. European Journal of Neurology, 2022, 29, 1311-1323.	3.3	27
98	Molecular mechanisms mediating pathological plasticity in Huntington's disease and Alzheimer's disease. Journal of Neurochemistry, 2007, 100, 874-882.	3.9	26
99	The Calcium-Binding Protein EFhd2 Modulates Synapse Formation In Vitro and Is Linked to Human Dementia. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1166-1182.	1.7	25
100	Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. Acta Neuropathologica Communications, 2015, 3, 53.	5.2	25
101	Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses. Acta Neuropathologica Communications, 2014, 2, 63.	5.2	24
102	Monitoring protein aggregation and toxicity in Alzheimerâ€™s disease mouse models using in vivo imaging. Methods, 2011, 53, 201-207.	3.8	22
103	A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Research, 2009, 1280, 178-185.	2.2	20
104	Conditional Deletion of PDK1 in the Forebrain Causes Neuron Loss and Increased Apoptosis during Cortical Development. Frontiers in Cellular Neuroscience, 2017, 11, 330.	3.7	20
105	Non-Invasive RF Technique for Detecting Different Stages of Alzheimerâ€™s Disease and Imaging Beta-Amyloid Plaques and Tau Tangles in the Brain. IEEE Transactions on Medical Imaging, 2020, 39, 4060-4070.	8.9	20
106	Opposing Roles of apolipoprotein E in aging and neurodegeneration. Life Science Alliance, 2019, 2, e201900325.	2.8	20
107	The Synthesis of Megatubes:Â New Dimensions in Carbon Materials. Inorganic Chemistry, 2001, 40, 2751-2755.	4.0	18
108	Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2022, 59, 683-702.	4.0	18

#	Article	IF	Citations
109	Amyloidâ€beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. Alzheimer's and Dementia, 2016, 12, 996-1013.	0.8	17
110	Modeling Alzheimerâ€™s disease brains in vitro. Nature Neuroscience, 2018, 21, 899-900.	14.8	17
111	Tackling gaps in developing lifeâ€changing treatments for dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 241-253.	3.7	17
112	Sleep well to slow Alzheimer's progression?. Science, 2019, 363, 813-814.	12.6	17
113	Clearing the way for tau immunotherapy in Alzheimer's disease. Journal of Neurochemistry, 2015, 132, 1-4.	3.9	16
114	Opening up: open access publishing, data sharing, and how they can influence your neuroscience career. European Journal of Neuroscience, 2016, 43, 1413-1419.	2.6	16
115	Generation of twenty four induced pluripotent stem cell lines from twenty four members of the Lothian Birth Cohort 1936. Stem Cell Research, 2020, 46, 101851.	0.7	16
116	Creating and Validating a DNA Methylation-Based Proxy for Interleukin-6. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2284-2292.	3.6	16
117	Potential neurobiological links between social isolation and Alzheimer's disease risk. European Journal of Neuroscience, 2022, 56, 5397-5412.	2.6	16
118	Two postprocessing techniques for the elimination of background autofluorescence for fluorescence lifetime imaging microscopy. Journal of Biomedical Optics, 2008, 13, 014008.	2.6	15
119	Childhood intelligence attenuates the association between biological ageing and health outcomes in later life. Translational Psychiatry, 2019, 9, 323.	4.8	15
120	Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis postâ€mortem motor cortex and cerebrospinal fluid. Brain Pathology, 2022, 32, e13035.	4.1	15
121	T cell mediated cerebral hemorrhages and microhemorrhages during passive AÎ² immunization in APPPS1 transgenic mice. Molecular Neurodegeneration, 2011, 6, 22.	10.8	14
122	High neural activity accelerates the decline of cognitive plasticity with age in Caenorhabditis elegans. ELife, 2020, 9, .	6.0	12
123	Endogenous Tau Aggregates in Oligodendrocytes of rTg4510 Mice Induced by Human P301L Tau. Journal of Alzheimer's Disease, 2013, 38, 589-600.	2.6	11
124	MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia. Brain Communications, 2021, 3, fcab114.	3.3	11
125	sAPPÎ² and sAPPÎ± increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Ca2+ homeostasis and CREB1-signaling. Experimental Neurology, 2018, 304, 1-13.	4.1	9
126	A comparison of blood and brainâ€derived ageing and inflammationâ€related DNA methylation signatures and their association with microglial burdens. European Journal of Neuroscience, 2022, 56, 5637-5649.	2.6	9

#	Article	IF	Citations
127	Complementing Tau: New Data Show that the Complement System Is Involved in Degeneration in Tauopathies. Neuron, 2018, 100, 1267-1269.	8.1	8
128	A brain boost to fight Alzheimer's disease. Science, 2018, 361, 975-976.	12.6	8
129	Microglial contribution to synaptic uptake in the prefrontal cortex in schizophrenia. Neuropathology and Applied Neurobiology, 2021, 47, 346-351.	3.2	7
130	Epigenetic predictors of lifestyle traits applied to the blood and brain. Brain Communications, 2021, 3, fcab082.	3.3	6
131	Reducing voltage-dependent potassium channel Kv3.4 levels ameliorates synapse loss in a mouse model of Alzheimerâ€™s disease. Brain and Neuroscience Advances, 2022, 6, 239821282210864.	3.4	6
132	Gender representation in science publication: evidence from Brain Communications. Brain Communications, 2022, 4, .	3.3	6
133	Propagation of Tau Pathology in a Model of Early Alzheimerâ€™s Disease. Neuron, 2012, 76, 461.	8.1	5
134	You are not alone: selecting your group members and leading an outstanding research team. European Journal of Neuroscience, 2015, 42, 3012-3017.	2.6	4
135	Maintained memory and longâ€term potentiation in a mouse model of Alzheimer's disease with both amyloid pathology and human tau. European Journal of Neuroscience, 2021, 53, 637-648.	2.6	4
136	Loss of SORCS2 is Associated with Neuronal DNA Double-Strand Breaks. Cellular and Molecular Neurobiology, 2023, 43, 237-249.	3.3	4
137	Using R to improve rigour and transparency in translational neuroscienceâ€”or is it just a rabbit hole?. Brain Communications, 2022, 4, fcab290.	3.3	4
138	Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review. European Journal of Neuroscience, 2022, 56, 5650-5713.	2.6	4
139	Pathology of Synapses and Dendritic Spines. Neural Plasticity, 2012, 2012, 1-2.	2.2	3
140	Dysregulation in Subcellular Localization of Myelin Basic Protein mRNA Does Not Result in Altered Myelination in Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2021, 15, 705306.	2.8	3
141	Editorial. Brain Communications, 2020, 2, fcz051.	3.3	2
142	TMEM97 is a potential amyloid beta receptor in human Alzheimerâ€™s disease synapses. Alzheimer's and Dementia, 2020, 16, e041782.	0.8	2
143	OUP accepted manuscript. Brain Communications, 2021, 3, fcab217.	3.3	2
144	Assessing amyloid-Î², tau, and glial features in Lothian Birth Cohort 1936 participants post-mortem. Matters, 0, , .	1.0	2

#	Article	IF	Citations
145	Letâ€™s talk about sex (in translational neuroscience). Brain Communications, 2022, 4, fcac028.	3.3	2
146	Editorial. Brain Communications, 2019, 1, fcz001.	3.3	1
147	Toward a holistic model of Alzheimerâ€™s How Not to Study a Disease: The Story of Alzheimerâ€™s Karl Herrup MIT Press, 2021. 272 pp.. Science, 2021, 374, 267-267.	12.6	1
148	A role for astrocytes and microglia in synapse loss in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
149	An automatic method for spine detection and spine tracking in in vivo images. , 2007, , .		0
150	Spine tingling polymorphismsâ€"Is apolipoprotein E involved in dendritic shape and plasticity?. Neurobiology of Aging, 2007, 28, 687-688.	3.1	0
151	PL-05-01: A transgenic model of the earliest stage of Alzheimer's disease. , 2010, 6, S165-S165.		0
152	O1-05-01: APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease. , 2011, 7, S103-S104.		0
153	O2-01-01: Neurofibrillary tangles remain functionally integrated in cortical networks. , 2013, 9, P314-P314.		0
154	Analyzing Alzheimerâ€™s Disease-Related Protein Deposition In Vivo By Multiphoton Laser Scanning Microscopy. , 2014, , 97-104.		0
155	New terminology for a common TDP-43 proteinopathy. Lancet Neurology, The, 2019, 18, 714-715.	10.2	0
156	Editorial June 2020. Brain Communications, 2020, 2, fcaa106.	3.3	0
157	Editorial. Brain Communications, 2021, 3, fcaa225.	3.3	0
158	Editorial April 2021. Brain Communications, 2021, 3, fcab059.	3.3	0
159	Reducing Tau Ameliorates Behavioural and Transcriptional Deficits in a Novel Model of Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	0
160	Tau talk â€“ synaptic and mitochondrial proteins interact with Tau in human neurons. Trends in Neurosciences, 2022, , .	8.6	0
161	OUP accepted manuscript. Brain Communications, 2022, 4, fcac099.	3.3	0